Default Category
-
Measuring Impairment at Dofasco
Mary Gillett; Mary-Jane MastrandreaCase IVEY-9B09B017-EAccounting and ControlIn December 2008, the ArcelorMittal Dofasco (Dofasco) accounting team was facing a significant challenge. In the past few years, Dofasco had undergone significant ownership changes, and when the firm had first been acquired the market had placed a premium share value on the Dofasco subsidiary. In light of a recent economic downturn, the accounting team was required to reassess the values assigned to the subsidiary's net assets. Dismal forecasted ...Starting at €8.20
-
Cells For Life (B)
John G. Wilson; Robert Young; Georg Oppitz; Wayne Hoy; David BassinCase IVEY-9B09E011-ECorporate Governance, Service and Operations ManagementA biotech company receives umbilical cells for processing. A number of operational improvements are being considered in order to maintain the company's position and reputation in the market. Information on expected delivery dates is known. However, there is a great uncertainty around these dates. The company needs to take account of this variability when arranging for staffing.Starting at €5.74
-
Cells For Life (A)
John G. Wilson; Robert Young; Georg Oppitz; Wayne Hoy; David BassinCase IVEY-9B09E010-ECorporate Governance, Service and Operations ManagementA biotech company receives umbilical cells for processing. A number of operational improvements are being considered in order to maintain the company's position and reputation in the market. Information on expected delivery dates is known. However, there is a great uncertainty around these dates. The company needs to take account of this variability when arranging for staffing. A supporting data set is available, product 7B09E010 for the (A) case...Starting at €8.20
-
Accounting at Biovail - Revised
Mary Gillett; Mary-Jane Mastrandrea; Jessica FrischCase IVEY-9B09B004-EAccounting and ControlBiovail was a large international pharmaceutical company with reported revenues of $788 million. Banc of America has issued a research report which indicates that Biovail Corporation's financial statements raised a number of issues that warrant caution for investors, and as a result, Biovail's stock was given a sell rating by Banc of America. A member of Biovail's audit committee is preparing for an upcoming audit meeting and considers the implic...Starting at €8.20